ClinicalTrials.gg
RecruitingNCT06955897Updated Oct 14, 2026

Characterizing Perceived Physical Fatigability in Nusinersen-treated SMA

An observational study in Spinal Muscular Atrophy, sponsored by Columbia University. Recruiting at 1 site in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Columbia University · Observational

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.
Updated Oct 14, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 121 studies in Muscular Atrophy, Spinal with a site in United States — 21 open to participants now, 39 under way, 7 of them phase 3. Muscular Atrophy, Spinal · United States.

Planned enrollment
26th of 43
45 · median 75
Started
2025
with 7 others
Observational
43 of 121
11 open now
Primary completion
2027-09
later than 13 of 38 live
Registered
107th of 121
by date
Lead sponsor
9 of 121
Columbia University

Among the 121 studies in Muscular Atrophy, Spinal with a site in United States, this one is the 26th largest by planned enrollment of the 43 observational ones that give a count, is one of 8 that started in 2025, is one of 43 observational ones, reaches primary completion later than 13 of the 38 other live ones, and was the 107th registered.

Muscular Atrophy, Spinal

282 studies on the registry are indexed under Muscular Atrophy, Spinal; 71 are open to participants now.

Browse Muscular Atrophy, Spinal studies →

Open to participants now

21 of the 121 studies in Muscular Atrophy, Spinal with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 56 Muscular Atrophy, Spinal studies recruiting now, 28 (50%) set no upper age limit and 25 (45%) stop at 75 or younger; 44 take children under 18; 11 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies in Muscular Atrophy, Spinal with a site in United States, or all of them as a file.
02

Study summary

The purpose of this project is to investigate the utility of the SMA EFFORT, an SMA-specific patient-reported outcome measure, to assess perceived physical fatigability that is anchored to intensity and duration of activities. We aim to characterize perceived physical fatigability (PPF) in a diverse cohort of people with SMA (pwSMA) and evaluate the change of PPF before and after nusinersen dosing.

Read the detailed description

Fatigue and fatigability are symptoms often experienced by people living with spinal muscular atrophy (pwSMA). Nusinersen is shown to extend survival and improve motor function, but fatigue and fatigability persist. Treated patients report changes in their ability to complete repetitive physical activities but a way for measuring this has not been created. While tests completed in the clinic by individuals with SMA highlight that fatigability is an important part of the SMA experience,we do not fully understand how pwSMA experience fatigability with everyday tasks. Anecdotal reports of pwSMA suggest a waning effect in endurance toward the end of their treatment window, however this change has not been measured.The SMA EFFORT is specifically designed for pwSMA and aims to better understand how they feel when completing daily physical activities.

03

Conditions studied

  • Spinal Muscular Atrophy

Keywords

  • spinal muscular atrophy
  • neuromuscular disease
  • nusinersen
  • fatigability
  • exercise
  • SMA
  • fatigue
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

12 years and older, with genetic diagnosis of all types of 5qSMA, treated with nusinersen (12 or 28 mg) for at least 6 months, will be included.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. All types of 5qSMA (homozygous deletion or point mutation of the SMN1 gene and any number of SMN2 copies)
  2. Receiving a stable dosing regimen of 12 or 28 mg nusinersen for at least 6 months

Exclusion criteria

Exclusion Criteria:

  1. An injury or surgery within the previous 3 months that would impact their ability to perform in-clinic function and/or fatigability assessments
  2. Enrolled in an ongoing clinical trial, or extension study, expanded access program, or long-term registry of an or recently approved medication
  3. Receiving and/or dual therapy (e.g., muscle-targeted, NMJ, or symptomatic treatments)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45 participants (estimated)
Patient registry
No

Groups and cohorts

  • Walkers

    Participants with SMA who are able to walk without assistance.

    Other: Observational

  • Sitters

    Participants with SMA who are unable to walk without assistance, but are able to sit independently.

    Other: Observational

  • Non-sitters

    Participants with SMA who are unable to sit without assistance.

    Other: Observational

Interventions

  • OtherObservational

    Observational

06

What researchers measure

Primary outcomes

  1. SMA EFFORT

    The SMA EFFORT is a perceived physical fatigability patient-reported outcome measure (PROM) that provides a percent (PPF%) total score to each participant based on their participation over the past 30 days.

    Time frame: Baseline, 1 week, 1 month

Secondary outcomes

  1. Revised Upper Limb Module (RULM)

    The RULM is used to assess motor function of the shoulder, mid-level elbow, wrist, and hand.

    Time frame: Baseline

  2. Hammersmith Functional Motor Scale Expanded (HFMSE)

    The HFMSE is a 33-item scale designed to assess gross motor function in sitters and walkers with SMA.

    Time frame: Baseline

  3. Six-Minute Walk Test (6MWT)

    The 6MWT is an objective evaluation of functional exercise capacity which measures the maximum distance a person can walk in six minutes over a 25-meter linear course.

    Time frame: Baseline

  4. Six-Minute Mastication Test (6MMT)

    The 6MMT is a measure of chewing endurance in which the individual is asked to continuously chew on a chewing tube for a period of six minutes.

    Time frame: Baseline

  5. Endurance Shuttle Box and Block Test (ESSBT)

    The ESSBT is a test of upper limb function that has been adapted to assess performance fatigability in SMA.

    Time frame: Baseline

  6. Endurance Shuttle Nine-Hole Peg Test (ESNHPT)

    The ESNHPT is used to assess more distal, fine motor upper extremity performance fatigability.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Sep 2027, 28 months after the start.

Of 58 observational studies under Muscular Atrophy, Spinal, half reached primary completion within 88 months of starting (the median), counting those still running; a quarter within 36. This study's planned 28 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Dec 2026 → Sep 2027 and completion Feb 2027 → Mar 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 25, 2025
First posted
May 2, 2025
StartActual
Apr 24, 2025
Primary completionEst.
Sep 6, 2027was Dec 2026
CompletionEst.
Mar 26, 2028was Feb 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 7, 2026→Sep 6, 2027
Oct 14, 2026
Study completion
Feb 26, 2027→Mar 26, 2028
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Primary completion Dec 7, 2026→Sep 6, 2027
    Study completion Feb 26, 2027→Mar 26, 2028

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06955897
Collaborators
Biogen
Responsible party
Jacqueline Montes (Professor of Rehabilitation and Regenerative Medicine, Columbia University) — Principal investigator
First posted
May 2, 2025
Start date
Apr 24, 2025
Primary completion
Sep 6, 2027 (estimated)
Completion
Mar 26, 2028 (estimated)
Last update
Oct 14, 2026

Study contacts

Rafael Rodriguez-Torres, DPT
Contact
rsr2157@cumc.columbia.edu
3472877093
Cara Kanner, DPT
Contact
chy2112@cumc.columbia.edu
516-581-8150
Jacqueline Montes, Pt, EdD
principal investigator · Columbia University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion